スウェーデン・ルンド大学の研究者らが、体が損傷した骨を修復するよう導く無細胞軟骨スキャフォールドを作成した。この革新は動物モデルで成功裏にテストされ、強い免疫反応を回避し、患者特異的移植片の普遍的な代替を提供する。人での臨床試験に向けた計画が進行中だ。
骨や骨格の損傷は世界中で長期的な障害を引き起こすことが多く、特にがん治療、重度の関節疾患（リウマチ性関節炎や変形性関節症）、または深刻な感染症の場合である。大きな骨の部分が損傷すると、体は自然に修復できない場合があり、移植が必要となる。毎年、世界で200万人以上が骨移植手術を受けている。
AIによるレポート AIによって生成された画像 事実確認済み
Northwestern University researchers say they developed an advanced lab-grown human spinal cord organoid model that reproduces key features of traumatic injury—such as inflammation and glial scarring—and that an experimental “dancing molecules” therapy reduced scar-like tissue and promoted nerve-fiber growth in the model.
Scientists at ETH Zurich have invented a hydrogel implant that mimics the body's natural bone healing process. Composed mostly of water, the material can be precisely shaped using lasers to create detailed structures resembling bone tissue. This innovation aims to offer a better alternative to traditional grafts and metal implants.
AIによるレポート
An experimental therapy using stem cells from young donors has shown promise in improving mobility for frail older people. In a trial involving 148 participants, infusions of laromestrocel led to significant gains in walking distance. Researchers highlight its potential to address biological roots of frailty.
Researchers at UCLA have identified senescent immune cells, dubbed 'zombie' cells, that accumulate in aging livers and contribute to fatty liver disease. By eliminating these cells in mice, the team reversed liver damage and reduced body weight, even on an unhealthy diet. The findings, published in Nature Aging, suggest similar mechanisms may drive human liver conditions.
AIによるレポート
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.